US 11,781,247 B2
Variable epitope library compositions and methods of therapeutic and prophylactic use
Karen Manucharyan, Mexico City (MX); and Gohar Gevorgyan, Mexico City (MX)
Assigned to Primex Clinical Laboratories, Inc., Van Nuys, CA (US)
Filed by Primex Clinical Laboratories, Inc., Van Nuys, CA (US)
Filed on Aug. 19, 2019, as Appl. No. 16/544,189.
Application 16/544,189 is a continuation of application No. 14/991,807, filed on Jan. 8, 2016, granted, now 10,383,927, issued on Aug. 20, 2019.
Claims priority of provisional application 62/101,874, filed on Jan. 9, 2015.
Prior Publication US 2019/0374625 A1, Dec. 12, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. C40B 30/06 (2006.01); A61K 39/00 (2006.01)
CPC C40B 30/06 (2013.01) [A61K 39/00115 (2018.08); A61K 2039/572 (2013.01); A61K 2039/80 (2018.08)] 13 Claims
OG exemplary drawing
 
1. A method of treating cancer in a subject, the method comprising:
administering a variable epitope library vaccine composition comprising one or more synthetic isolated peptides having amino acid sequences corresponding to an epitope of a tumor antigen that is essential for tumor survival and expressed by said tumor at high levels, or nucleic acid encoding said synthetic isolated peptides, said one or more peptides having from about 7 to about 50 total amino acids, wherein from about 1% to about 50% of the total amino acids of the one or more peptides are variable amino acids, and a pharmaceutically acceptable excipient; wherein the composition generates an immune response when administered to the subject, and wherein said cancer if present in said subject, has a mass of less than 10 mm2, wherein the tumor antigen is survivin comprising a CTL epitope, wherein the survivin CTL epitope is the peptide represented by GWEPDDNPI (SEQ ID NO: 2) having variable amino acids at positions 3, 5 and 7 (GWXPXDXPI (SEQ ID NO: 1)).